Incannex Healthcare (ASX: IHL) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Incannex Healthcare Chart and Price Data

Fundamentals Data provided by Morningstar.

Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Incannex Healthcare (ASX: IHL)
    Latest News

    A couple are shocked and elated at the good news they've just seen on their devices.
    Share Gainers

    Why Core Lithium, European Lithium, Incannex, and Qantas shares are pushing higher

    These ASX shares are ending the week strongly...

    Read more »

    Researcher putting cannabis leaf in test tube.
    Share Fallers

    The Incannex share price has plunged 70% so far in 2022. What's gone so wrong?

    Downside continues over the past month for the cannabis stock.

    Read more »

    Three people sit on safe cheering with pizza on table
    Share Gainers

    3 ASX All Ordinaries shares going great guns on Thursday

    It's a good day to be invested in these stocks.

    Read more »

    An older farmer wearing a checkered shirt and a straw hat stands in a green field of cannabis plants growing up to waist level as he smiles while thinking about the outlook for ASX cannabis shares in FY23
    Cannabis Shares

    Green shoots or just weeds? The outlook for ASX cannabis shares in FY23

    Are cannabis stocks set to rise along with the broader industry in the new financial year?

    Read more »

    A woman wearing a pink blouse and straw hat holds up a cannabis leaf with tall green cannabis plants in the background
    Cannabis Shares

    How did ASX cannabis shares perform in FY22?

    Here's a look at the sector's performance in the financial year just gone.

    Read more »

    Two researchers discussing results of a study with each other.
    Healthcare Shares

    Here's how ASX 200 healthcare shares performed in June

    Healthcare shares were a tad ill in June.

    Read more »

    a group of five women in business attire stand side by side with unhappy looks on their faces and holding their thumbs down.
    Share Market News

    5 worst ASX All Ordinaries shares in June

    Negative sentiment towards these five ASX shares resulted in big price declines in June. Here's why.

    Read more »

    A woman wearing a pink blouse and straw hat holds up a cannabis leaf with tall green cannabis plants in the background
    Cannabis Shares

    Remember when ASX cannabis shares were smoking hot? Where are they now?

    Newly legalised recreational and medicinal marijuana markets aren't getting the media hype they once did.

    Read more »

    A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
    Healthcare Shares

    Incannex share price pops 9% on FDA news

    The medicinal cannabis drug development company came out with some positive developments from its FDA meeting...

    Read more »

    Green stock market graph with a rising arrow symbolising a rising share price.
    Share Gainers

    Why CBA, Incannex, Judo Capital, and Orica shares are rising

    These ASX shares are avoiding the market selloff...

    Read more »

    Rising marijuana share price.
    Cannabis Shares

    Here's why the Incannex share price is rocketing 18% today

    Incannex provided an update on the APIRx takeover.

    Read more »

    A dollar sign embedded in ice, indicating a share price freeze or trading halt
    Healthcare Shares

    Down 25% in a month, the Incannex share price is now halted. Here's why

    A key update awaits the market from Incannex.

    Read more »

    Frequently Asked Questions

    Incannex listed on the ASX in May 2007.

    No, Incannex has not yet paid out any dividends.

    IHL ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Incannex Healthcare

    Incannex Healthcare Ltd (ASX: IHL) is a developer of cannabinoid and psychedelic compound medicines. It is currently involved in clinical programs for the treatment of six conditions: Obstructive Sleep Apnea (OSA), Generalised Anxiety Disorder (GAD), traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions.

    The company has an Australian license to import, export, and distribute medicinal cannabis products and has a line of cannabinoid products.

    The Incannex share price hit an all-time high of $5.36 a couple of months after listing in May 2007 before plunging to its current levels.

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    31 Oct 2023 Peter Widdows Buy 230,954 $15,296
    On-market trade. As per announcement on 07-11-2023
    31 Oct 2023 Peter Widdows Buy 280,000 $18,545
    On-market trade.
    02 Jun 2023 Troy Valentine Buy 2,443,413 $2,443
    As advised by the company. Purchase of Loyalty Options
    02 Jun 2023 Peter Widdows Buy 1,104,913 $1,104
    As advised by the company. Purchase of Loyalty Options
    02 Jun 2023 Joel Latham Buy 1,583,227 $1,583
    As advised by the company. Purchase of Loyalty Options

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Troy Robert Valentine Non-Executive ChairmanNon-Executive Director Dec 2017
    Troy Valentine has been Chairman of the Board of Directors since December 2017. Mr. Valentine is a finance professional with managerial and Board experience spanning over 27 years. He commenced his career with Australian brokerage firm Hartley Poynton (now Euroz Hartley s Limited) in 1994 before moving to Patersons Securities (now Canaccord Genuity) in 2000 and subsequently became an Associate Director. During his time at Patersons, he was responsible for managing both retail and institutional accounts. Mr. Valentine has significant corporate and capital raising experience, especially with start-ups and small to mid-cap size companies. He is currently a director of Australian boutique corporate advisory firm Alignment Capital Pty Ltd, which he co-founded in 2014.
    Mr Peter Widdows Non-Executive Director Mar 2018
    Mr Valentine has been Chairman of the Board of Directors since December 2017. Mr. Valentine is a finance professional with managerial and Board experience spanning over 27 years. He commenced his career with Australian brokerage firm Hartley Poynton (now Euroz Hartleys Limited) in 1994 before moving to Patersons Securities (now Canaccord Genuity) in 2000 and subsequently became an Associate Director. During his time at Patersons, he was responsible for managing both retail and institutional accounts. Mr. Valentine has significant corporate and capital raising experience, especially with start-ups and small to mid-cap size companies. He is currently a director of Australian boutique corporate advisory firm Alignment Capital Pty Ltd, which he co-founded in 2014.
    Mr Joel Bradley Latham Chief Executive OfficerExecutive DirectorManaging Director Jul 2018
    Joel Latham is the CEO and Managing Director of Incannex Healthcare and is responsible for the Companys commercial operations, strategic decision- making, and oversight of all clinical development assets. Joel has over 15 years commercial management and executive experience, working for a range multi-national publicly traded companies.
    Dr George Anastassov Non-Executive Director Jun 2022
    Dr Anastassov is responsible for APIRx commercial operations, strategic decision-making, and oversight of all clinical development assets. He is one of the developers of the first-in-the world cannabinoid-containing chewing gum-based delivery system among a number of other systems and formulations. Previously, he was CEO and co-founder of AXIM Biotechnologies, which achieved an all-time-high market capitalization of approximately US$1.2B.
    Mr Lekhram Changoer Non-Executive Director Jun 2022
    --
    Mr Robert Bruce Clark Non-Executive Director Aug 2022
    Mr Clark is a senior-level strategic regulatory affairs expert with over 38 years of US and Global regulatory experience, including >20 years with Pfizer Inc. and >10 years with Novo Nordisk A/S. He is an internationally recognized expert on US Food and Drug Administration ('FDA') and the European Medicines Agency (EMA) liaison interactions, US pharmaceutical advertising practices and regulatory aspects related to healthcare professionals and sales force activities. Mr Clark is Vice President, US Regulatory Affairsfor Novo Nordisk where he provides strategic leadership to a team of over 50 regulatory staff and scientists in the development of new medicines. He advises the global executive team on matters related to drug development programs, FDA liaison strategies, managing FDA-related compliance issues, and monitoring emerging US regulatory trends and opportunities.
    Mr Madhukar (Madhu) Bhalla Company Secretary Jul 2021
    -
    Madhukar (Madhu) Bhalla Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 82,707,741 5.23%
    George Anastassov 66,972,077 4.23%
    Prasch Bv 63,954,841 4.04%
    Dr Sudhanshu Agarwal 34,080,364 2.15%
    Cannvalate Pty Ltd 32,000,000 2.02%
    Mr Raymond Laurence Carroll 30,250,000 1.91%
    J P Morgan Nominees Australia Pty Limited 23,906,440 1.51%
    Brownarrows Pty Ltd <Ejm A/C> 23,610,000 1.49%
    BNP Paribas Noms Pty Ltd Deutsche Bank Tca <Drp> 22,880,950 1.45%
    Citicorp Nominees Pty Limited 19,087,124 1.21%
    Mr Peter Widdows 15,973,694 1.01%
    Mr Kaide Wang 15,700,000 0.99%
    IMI LLC 14,642,234 0.93%
    Bagbo Pty Ltd 14,516,434 0.92%
    Mr Brian Peter Byass 14,247,191 0.90%
    Mr Joel Bradley Latham 13,829,129 0.87%
    Gemini Capitall Llc <The Ars A/C> 13,787,086 0.87%
    Slade Technologies Pty Ltd <Embrey Family S/F A/C> 13,350,000 0.84%
    Alignment Capital Pty Ltd 13,194,248 0.83%
    Ryba Llc 13,090,170 0.83%

    Profile

    since

    Note